Novel therapeutic targets in cancer

Details for Australian Patent Application No. 2004276821 (hide)

Owner Chiron Corporation

Inventors Malandro, Marc S.; Morris, David W.

Agent FB Rice

Pub. Number AU-A-2004276821

PCT Pub. Number WO2005/031001

Priority 10/669,920 23.09.03 US

Filing date 23 September 2004

Wipo publication date 7 April 2005

International Classifications

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/031001 Priority application(s): WO2005/031001

20 November 2008 Alteration of Name

  The name of the applicant has been altered to Novartis Vaccines and Diagnostics, Inc.

13 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004276823-Synthetic lethal screen using RNA interference

2004276820-Analyzing histamine H4 receptor-mediated effects in whole blood